<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937846</url>
  </required_header>
  <id_info>
    <org_study_id>110771</org_study_id>
    <nct_id>NCT00937846</nct_id>
  </id_info>
  <brief_title>Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study</brief_title>
  <official_title>An Open Label Positron Emission Tomography (PET) Study to Investigate Brain Penetration by [Carbonyl-11C] GSK1034702 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      GSK1034702 is being developed for improving cognitive impairment in diseases such as
      Alzheimer's disease and schizophrenia. This study will be done in healthy men to investigate
      how much of the study drug gets into the brain. This will be done using Positron Emission
      Tomography (PET).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single dose, non-randomized PET study in healthy male subjects to
      ascertain if GSK1034702 is crossing the blood-brain barrier to enable it to elicit a central
      effect. GSK1034702 has been shown in vitro to be a substrate for human Pgp, therefore the
      distribution of GSK1034702 into human brain could be adversely affected. This use of PET in
      conjunction with radioactively labelled GSK1034702 will help ascertain the role Pgp plays in
      limiting brain penetration in the presence and absence of a pharmacological relevant oral non
      labelled dose of 5 mg. Subjects will have an MRI scan to aid definition of brain anatomy, a
      baseline PET scan and a post-dose PET scan. For each subject the study will consist of at
      least three visits; screening visit, scanning day and follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2009</start_date>
  <completion_date type="Actual">August 28, 2009</completion_date>
  <primary_completion_date type="Actual">August 28, 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Volume of distribution of [11C]GSK1034702 at tracer and pharmacological doses.</measure>
    <time_frame>Scanning day</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The kinetic rate constants at tracer and pharmacological doses.</measure>
    <time_frame>Scanning day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GSK1034702 PK parameters: Cmax; tmax; AUC(0-t).</measure>
    <time_frame>Scanning day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability endpoints consisting of: AEs; 12-lead ECG; 12 lead digital Holter and lead II telemetry; vital signs; clinical laboratory evaluations.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Cognitive Disorders</condition>
  <arm_group>
    <arm_group_label>GSK1034702</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral 5 mg dose in liquid formulation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1034702</intervention_name>
    <description>Single oral 5 mg dose in liquid formulation</description>
    <arm_group_label>GSK1034702</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy.

          -  Male between 35 and 55 years of age.

          -  Willing to use appropriate contraception method.

          -  Weight more than 50 kg.

          -  BMI within the range 19 - 29 kg/m2.

          -  Adequate blood supply to the hand.

        Exclusion Criteria:

          -  Abuse of drugs or alcohol.

          -  Smoker or history of regular use of tobacco- or nicotine-containing products in the
             past 6 months.

          -  ECG abnormality (personal or family history).

          -  Psychiatric disorder.

          -  Asthma or a history of asthma.

          -  Medical illness.

          -  Worked as a welder, metal worker or machinist.

          -  Suffers from claustrophobia or would be unable to lie still in a PET or MRI scanner
             for 1-2 hours.

          -  Has a cardiac pacemaker or other electrical device or ferromagnetic metal foreign
             bodies.

          -  Neurological disorder
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>W12 ONN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/110771?search=study&amp;study_ids=110771#rs</url>
    <description>Results for study 110771 can be found on the GSK Clinical Study Register.</description>
  </link>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>June 26, 2017</last_update_submitted>
  <last_update_submitted_qc>June 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cognitive impairment</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>PET</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>110771</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110771</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110771</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110771</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110771</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110771</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>110771</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

